30.12.2016
Evotec AG DE0005664809
DGAP-News: EVOTEC TO ATTEND THREE UPCOMING INVESTOR CONFERENCES
DGAP-News: Evotec AG / Key word(s): Conference
EVOTEC TO ATTEND THREE UPCOMING INVESTOR CONFERENCES
30.12.2016 / 11:33
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Hamburg, Germany, 30 December 2016:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)
announced today that its management will be presenting at the 16th German
Corporate Conference 2017 in Frankfurt, Germany, and will be attending 20th
ODDO Forum, Lyon, France, and 35th Annual J.P. Morgan Healthcare
Conference, San Francisco, USA.
20th ODDO Forum, Lyon, France
Date: Thursday, 05 January 2017
Venue: Lyon, France
Attendee: Enno Spillner, Chief Financial Officer of Evotec AG
35th Annual J.P. Morgan Healthcare Conference, San Francisco, USA
Date: Monday, 09 January, until Thursday, 12 January 2017
Venue: San Francisco, USA
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG
16th German Corporate Conference 2017, Frankfurt, Germany
Date: Wednesday, 18 January 2017, 03.30 pm CET (02.30 pm
GMT/09.30 am EST)
Venue: Frankfurt, Germany
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and
development partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with Sanofi in the field of diabetes and with Pfizer
in the field of tissue fibrosis. For additional information please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
30.12.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
533403 30.12.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT